Jim Cramer Discusses CVS Health (CVS) In Detail

We recently published 13 Stocks Jim Cramer Talked About.  CVS Health Corporation (NYSE:CVS) is one of the stocks that Jim Cramer talked about.

CVS Health Corporation (NYSE:CVS) is one of the largest pharmaceutical retailers in America. Its shares are up by 19.2% over the past year and are down by 2% year-to-date. In late January, Argus trimmed the firm’s share price target to $90 from $91 and kept a Buy rating on the shares. The financial firm pointed out that CVS Health Corporation (NYSE:CVS) would likely weather most of the impact from Medicare and Medicaid reimbursement rates remaining flat, particularly due to its diversified business model. In late January, Bank of America had cut CVS Health Corporation (NYSE:CVS)’s share price target to $95 from $100 and kept a Buy rating on the back of recent news in the Medicare and Medicaid sector. While analysts continue to discuss Medicare and Medicaid when it comes to CVS Health Corporation (NYSE:CVS), Cramer believes that developments in the pharmaceutical retail industry are beneficial for the firm:

Jim Cramer Discusses CVS Health (CVS) In Detail

“I think David Joiner is going to do well for CVS. Because, CVS is now the front of the store, it’s up against a decimated Wallgreens. A completely absent Rite Aid. And they’ve got a lot of great things in the back, and they’ve got, Aetna’s got a good plan. I bet you that’s the only one that comes out of this thing whole. Yeah, 11 times earnings, I like that. They report next week.”

While we acknowledge the risk and potential of CVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CVS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.